Edwards Lifesciences Corp. and Medtronic Inc. rose in New York trading after studies were released that will increase use of their man-made valves that can be inserted into the heart without cracking open the chest.
The battle for control of a developing market for heart valves that can be inserted without open-heart surgery intensified today as Edwards Lifesciences Corp.’s second-generation product was found to outperform Medtronic Inc.’s device in a head-to-head comparison.
Medtronic Inc.’s man-made aortic valve, inserted into the heart without cracking open the chest, reduced patient death rates more than open-heart surgery in the first study to ever record such a finding.
Abbott Laboratories’ experimental hepatitis C treatment cured almost half of patients who couldn’t eliminate the virus with therapies now on the market, according to a study that boosted the company’s shares.
Medtronic Inc.’s CoreValve replaced damaged aortic valves more safely than expected in patients who can’t tolerate traditional open-heart surgery, leading U.S. regulators to say it won’t need an advisory committee review.
Medtronic Inc. ghost-wrote sections of medical papers and paid physician authors hundreds of millions of dollars in “consulting fees” to promote its bone- growth product Infuse, a U.S. Senate investigation found.
Johnson & Johnson ’s antipsychotic medicine Risperdal Consta, its third-best-selling drug, fared no better than less expensive treatments at keeping schizophrenia patients out of the hospital, U.S. researchers said.